Sanofi reports data reinforcing efficacy of RSV candidate
![Photo: Benoit Tessier/Reuters/Ritzau Scanpix](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article14008679.ece/ALTERNATES/schema-16_9/20220204-123900-1-5954x3342ma.jpg)
On Wednesday, Sanofi reports a 79.5% efficacy for its respiratory syncytial virus (RSV) treatment candidate in infants with lower respiratory tract infections (LRTI), the company has announced in a press release.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Pfizer to acquire Reviral as RSV race continues
For subscribers